Prime Highlights
- Scientists developed HIV-seq, a tool that detects rare HIV-infected immune cells, revealing that some reservoir cells remain active even during antiretroviral therapy.
- The study shows these active cells produce viral fragments that can drive inflammation, organ damage, and increase the risk of viral rebound if treatment stops.
Key Facts
- Using HIV-seq, researchers identified 25 active reservoir cells in treated patients and over 1,000 infected cells in untreated patients, the highest count recorded so far.
- The research, conducted by Gladstone Institutesand San Francisco Veterans Affairs Medical Center, was published on March 3, 2026, in Nature Communications.
Background
Scientists have developed a new tool that offers deeper insight into how HIV persists in people receiving life-saving treatment. The tool, called HIV-seq, allows researchers to better detect and analyze rare HIV-infected immune cells that remain active even during antiretroviral therapy.
Antiretroviral therapy stops HIV from making full copies of itself. This keeps people with HIV healthy and reduces transmission. For years, scientists described infected immune cells as part of a “latent reservoir,” suggesting the virus inside them remains fully inactive. However, new findings show that some of these cells continue producing viral fragments. These fragments can fuel long-term inflammation, organ damage, and raise the risk of heart disease. They also increase the chances of viral rebound if treatment stops.
Researchers at Gladstone Institutes, working with experts at the San Francisco Veterans Affairs Medical Center, designed HIV-seq to overcome limits in traditional single-cell RNA sequencing. Standard methods often detected only one or two infected cells in treated patients, making a detailed study difficult.
Using HIV-seq, scientists identified 25 active reservoir cells from three people on therapy. In untreated patients, the tool captured more than 1,000 infected cells from four individuals, the highest number recorded so far.
The team found clear biological differences between cells before and after therapy. In untreated patients, infected cells appeared “fiery” and inflammatory. They carried proteins linked to killing other cells and showed low levels of genes tied to HIV suppression. In contrast, reservoir cells from treated patients appeared quieter. They showed anti-inflammatory features and produced more survival genes. These traits helped the cells live and stay in the body for many years.
These findings can help doctors plan better treatments in the future. Researchers are now testing if they can stop reservoir cells from multiplying by blocking the pathways that help these cells survive.
On March 3, 2026, Nature Communications published the study. The study shows an important step forward in understanding how HIV hides and stays alive even during treatment.
